Impact of sarcopenia in the management of urological cancer patients

References

• Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–423.
   PubMed Web of Science ®Google Scholar
• Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. J Cachexia Sarcopenia Muscle. 2015;7:290–298.
   PubMed Web of Science ®Google Scholar
• Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing. 2013;42:203–209.
   PubMed Web of Science ®Google Scholar
• Scott D, Daly RM, Sanders KM, et al. Fall and fracture risk in sarcopenia and dynapenia with and without obesity: the role of lifestyle interventions. Curr Osteoporos Rep. 2015;13:235–244.
   PubMed Web of Science ®Google Scholar
• Cosqueric G, Sebag A, Ducolombier C, et al. Sarcopenia is predictive of nosocomial infection in care of the elderly. Br J Nutr. 2006;96:895–901.
   PubMed Web of Science ®Google Scholar
• Kim JH, Cho JJ, Park YS. Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. J Korean Med Sci. 2015;30:264–271.
   PubMed Web of Science ®Google Scholar
• Lee J, Hong YP, Shin HJ, et al. Associations of sarcopenia and sarcopenic obesity with metabolic syndrome considering both muscle mass and muscle strength. J Prev Med Public Health. 2016;49:35–44.
   PubMedGoogle Scholar
• Onoue Y, Izumiya Y, Hanatani S, et al. A simple sarcopenia screening test predicts future adverse events in patients with heart failure. Int J Cardiol. 2016;215:301–306.
   PubMed Web of Science ®Google Scholar
• Kim TN, Choi KM. Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab. 2013;20:1–10.
   PubMedGoogle Scholar
• Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16:153–166.
   PubMed Web of Science ®Google Scholar
• Valero V 3rd, Amini N, Spolverato G, et al. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015;19:272–281.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Kato Y, Kudo M, et al. Preoperative sarcopenia strongly influences the risk of postoperative pancreatic fistula formation after pancreaticoduodenectomy. J Gastrointest Surg. 2016;20:1586–1594.
   PubMed Web of Science ®Google Scholar
• Ida S, Watanabe M, Yoshida N, et al. Sarcopenia is a predictor of postoperative respiratory complications in patients with esophageal cancer. Ann Surg Oncol. 2015;22:4432–4437.
   PubMed Web of Science ®Google Scholar
• Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41:333–338.
   PubMed Web of Science ®Google Scholar
• Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264–3268.
   PubMed Web of Science ®Google Scholar
• Martin L, Birdsell L, Macdonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–1547.
   PubMed Web of Science ®Google Scholar
• Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–635.
   PubMed Web of Science ®Google Scholar
• Harimoto N, Shirabe K, Yamashita YI, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013;100:1523–1530.
   PubMed Web of Science ®Google Scholar
• Peng P, Hyder O, Firoozmand A, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16:1478–1486.
   PubMed Web of Science ®Google Scholar
• Harada K, Ida S, Baba Y, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus. 2016; 29:627–633.
   Web of Science ®Google Scholar
• Go SI, Park MJ, Song HN, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7:567–576.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18:3579–3585.
   PubMed Web of Science ®Google Scholar
• Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127(5Suppl):990S–991S.
   PubMedGoogle Scholar
• Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97:2333–2338.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kaido T, Okumura S, et al. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. Nutrition. 2016;32:1200–1205.
   PubMed Web of Science ®Google Scholar
• Prado CM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3:269–275.
   PubMedGoogle Scholar
• Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–495.
   PubMed Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549–1555.
   PubMed Web of Science ®Google Scholar
• Cauley JA. An overview of sarcopenic obesity. J Clini Densitom. 2015;18:499–505.
   PubMed Web of Science ®Google Scholar
• Prado CM, Wells JC, Smith SR, et al. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012;31:583–601.
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
   PubMed Web of Science ®Google Scholar
• Choi Y, Oh DY, Kim TY, et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One. 2015;10:e0139749.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Yokoyama M, Nakanishi Y, et al. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS One. 2015;10:e0115895.
   Google Scholar
• Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014;210:489–497.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341.
   PubMed Web of Science ®Google Scholar
• Wan F, Zhu Y, Gu C, et al. Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer. World J Surg Oncol. 2014;12:14.
   PubMed Web of Science ®Google Scholar
• Smith AB, Deal AM, Yu H, et al. Sarcopenia as a predictor of complications and survival following radical cystectomy. J Urol. 2014;191:1714–1720.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Kondo T, Omae K, et al. Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study. Int J Clin Oncol. 2017; 22:136–144.
   Web of Science ®Google Scholar
• Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of complications in penile cancer patients undergoing inguinal lymph node dissection. World J Urol. 2015;33:1585–1592.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol. 2014;65:778–792.
   PubMed Web of Science ®Google Scholar
• Lawrentschuk N, Colombo R, Hakenberg OW, et al. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010;57:983–1001.
   PubMed Web of Science ®Google Scholar
• Raman JD, Messer J, Sielatycki JA, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107:1059–1064.
   PubMed Web of Science ®Google Scholar
• Hanna N, Sun M, Trinh QD, et al. Propensity-score-matched comparison of perioperative outcomes between open and laparoscopic nephroureterectomy: a national series. Eur Urol. 2012;61:715–721.
   PubMed Web of Science ®Google Scholar
• Bleeker MC, Heideman DA, Snijders PJ, et al. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009;27:141–150.
   PubMed Web of Science ®Google Scholar
• Protzel C, Alcaraz A, Horenblas S, et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009;55:1075–1088.
   PubMed Web of Science ®Google Scholar
• Antoun S, Baracos VE, Birdsell L, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594–1598.
   PubMed Web of Science ®Google Scholar
• Huillard O, Mir O, Peyromaure M, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108:1034–1041.
   PubMed Web of Science ®Google Scholar
• Cushen SJ, Power DG, Teo MY, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol. 2017; 40:47–52.
   PubMed Web of Science ®Google Scholar
• Ishihara H, Kondo T, Omae K, et al. Sarcopenia and the Modified Glasgow Prognostic Score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. Target Oncol. 2016;11:605–617.
   PubMed Web of Science ®Google Scholar
• McLaughlin JK, Lipworth L. Epidemiologic aspects of renal cell cancer. Semin Oncol. 2000;27:115–123.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol. 2012;30:1371–1377.
   PubMed Web of Science ®Google Scholar
• Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol. 2016;195:270–276.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Nakanishi Y, Kataoka M, et al. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol. 2016;195:26–32.
   PubMed Web of Science ®Google Scholar
• Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Urol Oncol. 2015;33(339):e17–23.
   Google Scholar
• Psutka SP, Carrasco A, Schmit GD, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014;120:2910–2918.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Nakanishi Y, Kataoka M, et al. Prognostic significance of sarcopenia in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Cancer Med. 2016;5:2213–2220.
   PubMed Web of Science ®Google Scholar
• Taguchi S, Akamatsu N, Nakagawa T, et al. Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma. Clin Genitourin Cancer. 2016;14:237–243.
   PubMed Web of Science ®Google Scholar
• Koo AS, Armstrong C, Bochner B, et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol Immunother. 1992;35:97–105.
   PubMed Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377–3384.
   PubMed Web of Science ®Google Scholar
• Abe T, Shinohara N, Harabayashi T, et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol. 2007;52:1106–1113.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Ohnishi S, et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis. Hepatol Res. 2016;46:743–751.
   PubMed Web of Science ®Google Scholar
• Stene GB, Helbostad JL, Amundsen T, et al. Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 2015;54:340–348.
   PubMed Web of Science ®Google Scholar
• Rutten IJ, van Dijk DP, Kruitwagen RF, et al. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. 2016;7:458–466.
   PubMed Web of Science ®Google Scholar
• Fukushima H, Nakanishi Y, Kataoka M, et al. Postoperative changes of skeletal muscle mass predict survival of metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy. Clin Genitourin Cancer. 2016. DOI:10.1016/j.clgc.2016.08.004. [Epub ahead of print]..
   PubMedGoogle Scholar
• Ahima RS, Park HK. Connecting myokines and metabolism. Endocrinol Metab (Seoul). 2015;30:235–245.
   PubMedGoogle Scholar
• Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–698.
   PubMed Web of Science ®Google Scholar
• Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604–3609.
   PubMed Web of Science ®Google Scholar
• Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013;4:95–109.
   PubMed Web of Science ®Google Scholar
• Cockbain AJ, Volpato M, Race AD, et al. Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Gut. 2014;63:1760–1768.
   PubMed Web of Science ®Google Scholar
• Stene GB, Helbostad JL, Balstad TR, et al. Effect of physical exercise on muscle mass and strength in cancer patients during treatment–a systematic review. Crit Rev Oncol Hematol. 2013;88:573–593.
   PubMed Web of Science ®Google Scholar
• Strasser B, Steindorf K, Wiskemann J, et al. Impact of resistance training in cancer survivors: a meta-analysis. Med Sci Sports Exerc. 2013;45:2080–2090.
   PubMed Web of Science ®Google Scholar
• Gould DW, Lahart I, Carmichael AR, et al. Cancer cachexia prevention via physical exercise: molecular mechanisms. J Cachexia Sarcopenia Muscle. 2013;4:111–124.
   PubMed Web of Science ®Google Scholar
• Pedersen L, Idorn M, Olofsson GH, et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 2016;23:554–562.
   PubMed Web of Science ®Google Scholar